BidaskClub lowered shares of Inogen (NASDAQ:INGN) from a hold rating to a sell rating in a research note released on Saturday morning.

A number of other analysts also recently commented on the stock. Leerink Swann reiterated an outperform rating and issued a $120.00 price objective (up previously from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Piper Jaffray Companies reiterated a hold rating and issued a $90.00 price objective on shares of Inogen in a report on Tuesday, September 12th. Zacks Investment Research upgraded shares of Inogen from a hold rating to a buy rating and set a $131.00 price objective for the company in a report on Thursday, November 9th. Finally, Needham & Company LLC increased their price objective on shares of Inogen from $108.00 to $125.00 and gave the company a strong-buy rating in a report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $102.71.

Inogen (INGN) opened at $117.75 on Friday. Inogen has a 1 year low of $62.69 and a 1 year high of $130.05. The firm has a market cap of $2,430.00, a PE ratio of 82.34, a P/E/G ratio of 4.06 and a beta of 1.13.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Tuesday, November 7th. The medical technology company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million during the quarter, compared to the consensus estimate of $63.55 million. During the same quarter in the prior year, the firm earned $0.25 EPS. The company’s revenue for the quarter was up 26.8% on a year-over-year basis. research analysts forecast that Inogen will post 1.19 earnings per share for the current year.

In other news, Director Raymond Huggenberger sold 14,000 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $94.07, for a total value of $1,316,980.00. Following the completion of the sale, the director now owns 7,808 shares of the company’s stock, valued at approximately $734,498.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $119.06, for a total transaction of $119,060.00. Following the completion of the sale, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $119,060. The disclosure for this sale can be found here. In the last three months, insiders sold 84,000 shares of company stock valued at $9,502,395. Corporate insiders own 5.31% of the company’s stock.

Several large investors have recently bought and sold shares of INGN. Koch Industries Inc. boosted its position in shares of Inogen by 19,485.8% during the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after purchasing an additional 653,747 shares during the period. Vanguard Group Inc. boosted its position in shares of Inogen by 24.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares during the period. New York State Common Retirement Fund boosted its position in shares of Inogen by 77.4% during the 2nd quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock worth $37,138,000 after purchasing an additional 169,778 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Inogen by 91.8% during the 2nd quarter. Goldman Sachs Group Inc. now owns 128,043 shares of the medical technology company’s stock worth $12,217,000 after purchasing an additional 61,291 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Inogen by 78.2% during the 3rd quarter. Prudential Financial Inc. now owns 124,088 shares of the medical technology company’s stock worth $11,801,000 after purchasing an additional 54,467 shares during the period.

TRADEMARK VIOLATION WARNING: “Inogen (INGN) Lowered to “Sell” at BidaskClub” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.watchlistnews.com/inogen-ingn-lowered-to-sell-at-bidaskclub/1800672.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.